HOUSTON, Texas — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided an update on the progress and clinical observations from the Phase 1 APOLLO study. The Company’s Phase 1 APOLLO...
treatment News
HOUSTON, Texas — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that data from the Phase 1 APOLLO study will be presented in two posters at the 67th American Society of Hematology (ASH)...
London — MarketsandMarkets is pleased to announce the 4th Annual Orphan Drugs and Rare Diseases Conference, which is set to take place on the 9th-10th of October 2023 in London, UK. After the resounding success of the third annual conference, we are excited to bring together industry experts, researchers, and...
Calgary, Alberta – Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBraiN Inserm Lab in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore...
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the “Company” or “Marvel”), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. The study evaluated MB-204, Marvel’s lead compound (10...
Columbus, Ohio – When Susan Powers went in for surgery to replace her hip in 2018, the last thing on her mind was cancer. But Powers’ pre-surgery blood work alarmed doctors enough that they recommended she see an oncologist immediately. Her daughter, Cheryl Spile, drove her to the hospital, where...
BEDMINSTER, N.J. — Matinas BioPharma (NYSE: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces alignment with the U.S. Food and Drug Administration (FDA) on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive...
First Patient Dosing Anticipated in Second Half of 2025 Additional Details to be Provided by Webinar in Coming Months MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has...
MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2 ASCEND-AS clinical trial of MVX-220, an investigational gene therapy for AS. The ASCEND-AS trial (NCT07181837) represents the...
MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MVX-220, an investigational adeno-associated virus (AAV) gene therapy for the treatment of AS. “The...